| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals
|
Jun 11, 2026 | BUY |
Strong Buy
+5.9% avg upside
18 analysts
|
— | -1.6% |
|
INCY
Incyte
|
Jun 08, 2026 | HOLD |
Buy
+1.0% avg upside
47 analysts
|
$103.00
6.95% Upside
|
-1.6% |
|
LEGN
Legend Biotech
|
Jun 04, 2026 | BUY |
Strong Buy
+115.9% avg upside
27 analysts
|
$49.00
69.74% Upside
|
+4.9% |
|
INSM
Insmed
|
Jun 03, 2026 | BUY |
Strong Buy
+80.3% avg upside
36 analysts
|
$166.00
72.27% Upside
|
-5.2% |
|
BHVN
Biohaven Ltd.
|
May 28, 2026 | HOLD |
Strong Buy
+88.9% avg upside
25 analysts
|
$11.00
18.09% Downside
|
+33.0% |
|
MPLT
MapLight Therapeutics, Inc.
|
May 27, 2026 | BUY |
Strong Buy
+30.8% avg upside
11 analysts
|
$48.00
65.37% Upside
|
-8.1% |
|
JAZZ
Jazz Pharmaceuticals
|
May 19, 2026 | BUY |
Strong Buy
-1.8% avg upside
35 analysts
|
$307.00
38.79% Upside
|
-2.9% |
|
CORT
Corcept Therapeutics
|
May 13, 2026 | BUY |
Buy
-46.3% avg upside
15 analysts
|
$72.00
10.90% Downside
|
+43.2% |
|
ALKS
Alkermes
|
May 06, 2026 | BUY |
Strong Buy
-16.4% avg upside
34 analysts
|
$48.00
8.94% Upside
|
+28.4% |
|
TEVA
Teva Pharmaceutical
|
Apr 30, 2026 | BUY |
Buy
-8.1% avg upside
39 analysts
|
$42.00
35.76% Upside
|
-3.9% |
|
RPRX
Royalty Pharma
|
Apr 20, 2026 | BUY |
Strong Buy
+3.4% avg upside
15 analysts
|
$57.00
11.36% Upside
|
+10.6% |
|
AXSM
Axsome Therapeutics
|
Apr 10, 2026 | BUY |
Strong Buy
-10.5% avg upside
28 analysts
|
$259.00
4.47% Upside
|
+41.4% |
|
NBIX
Neurocrine
|
Apr 06, 2026 | BUY |
Strong Buy
+8.0% avg upside
37 analysts
|
$161.00
2.79% Upside
|
+20.6% |
|
CYTK
Cytokinetics
|
Mar 24, 2026 | HOLD |
Strong Buy
+9.9% avg upside
36 analysts
|
$69.00
11.18% Downside
|
+31.6% |
|
ALVO
Alvotech
|
Mar 24, 2026 | BUY |
Buy
+104.7% avg upside
6 analysts
|
$6.00
54.26% Upside
|
+5.4% |
|
UTHR
United Therapeutics
|
Mar 05, 2026 | BUY |
Buy
-20.4% avg upside
26 analysts
|
$705.00
30.93% Upside
|
+13.7% |
|
VTRS
Viatris
|
Feb 27, 2026 | BUY |
Buy
+47.2% avg upside
21 analysts
|
$20.00
32.92% Upside
|
+6.9% |
|
ACAD
ACADIA Pharmaceuticals
|
Jan 05, 2026 | BUY |
Strong Buy
+66.6% avg upside
42 analysts
|
$40.00
87.55% Upside
|
-17.4% |
|
ABBV
AbbVie
|
Nov 07, 2025 | HOLD |
Buy
+1.2% avg upside
43 analysts
|
$220.00
1.82% Upside
|
+3.2% |
|
LLY
Eli Lilly & Co
|
Nov 07, 2025 | BUY |
Strong Buy
-11.3% avg upside
47 analysts
|
$1080.00
0.82% Downside
|
+23.2% |
|
EXEL
Exelixis
|
Nov 06, 2025 | HOLD |
Strong Buy
-21.4% avg upside
33 analysts
|
$40.00
21.84% Downside
|
+30.2% |
|
HRMY
Harmony Biosciences Holdings
|
Oct 14, 2025 | BUY |
Strong Buy
+38.7% avg upside
13 analysts
|
$43.00
29.97% Upside
|
+12.1% |
|
IMVT
Immunovant
|
Jul 29, 2025 | HOLD |
Strong Buy
+11.1% avg upside
24 analysts
|
$18.00
48.10% Downside
|
+108.5% |
|
CHRS
Coherus Biosciences
|
Jul 21, 2025 | HOLD |
Buy
+799.2% avg upside
18 analysts
|
$1.10
21.37% Downside
|
+66.9% |
|
BIIB
Biogen
|
Jul 14, 2025 | HOLD |
Strong Buy
+24.4% avg upside
51 analysts
|
$130.00
32.98% Downside
|
+50.3% |
|
RCKT
Rocket Pharmaceuticals
|
Jun 17, 2025 | BUY |
Buy
+418.9% avg upside
29 analysts
|
$5.00
53.76% Upside
|
+8.8% |
|
RANI
Rani Therapeutics Holdings
|
Oct 11, 2022 | BUY |
Strong Buy
+1131.4% avg upside
10 analysts
|
$15.00
1837.90% Upside
|
-75.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.